Tagged: Small cell lung cancer

Genprex Receives U.S. FDA Fast Track Designation for REQORSA® Immunogene Therapy in Combination with Tecentriq® for the Treatment of Small Cell Lung Cancer

Third FDA Fast Track Designation Further Validates the Potential of REQORSA

AUSTIN, Texas — (June 28, 2023) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the U.S.

Read More

Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer

Pipeline Expansion Enables Company to Target Entire Lung Cancer Market with REQORSA™

Read More